Julie Grant is a General Partner at Canaan, a tech and healthcare venture capital fund with $5B assets under management. She primarily leads investments and company formation efforts in biopharmaceuticals. Since joining Canaan in 2013, Julie has incubated, financed and supported investments in multiple new ventures including Day One, Nocion, Synthekine, Protagonist (PTGX), Cellular Research (Acquired by Becton Dickinson), Dermira (DERM), Labrys Biologics, CytomX (CTMX), Unchained Labs, Chrono Therapeutics, Genome Medical, Glooko, Vineti and Truveris. Prior to joining Canaan, Julie worked at Genentech in multiple capacities across development and commercial. She earned a B.S. in molecular biophysics and chemistry from Yale, an M.Phil. in bioscience enterprise from Cambridge, and an MBA from Stanford.
Copyright 2022 – Synthekine